Nexalin Technology Reports Q1 2025: Revenue Drops 48% with Significant Operating Losses

Nexalin Technology, Inc. (NASDAQ: NXL) reported its financial results for the first quarter ended March 31, 2025.

Key Points:

• Net Revenue: $41,015, a decrease of 48% compared to $78,671 in Q1 2024.
• Cost of Revenues: Increased to $13,558 from $9,156, reflecting a 48% rise.
• Gross Profit: Dropped to $27,457, down 61% from $69,515 in the same period last year.
• Total Operating Expenses: Increased to $2,038,682, up 78% from $1,143,227 in Q1 2024.
• Loss from Operations: Widened to $2,011,225, compared to $1,073,712 in Q1 2024.
• Net Loss: Totaled $1,988,337, up 91% from $1,041,157 in Q1 2024.
• Comprehensive Loss: Amounted to $1,987,507, significantly higher than $1,040,997 last year.

Income Statement Highlights:

• Positive Aspects:
  • Gross margin remained relatively high at 67%, though down from 88% in the prior year.
  • Other income increased, indicating effective management of investments.
• Negative Aspects:
  • Substantial increase in operating expenses, including professional fees and R&D costs.
  • Continued heavy losses due to high spending while revenues significantly declined.
  • Accumulated deficit rose to $86.6 million.

Liquidity & Capital Resources:

• Cash and equivalents amounted to approximately $622,000 as of March 31, 2025.
• Negative cash flows from operating activities were noted at $1.4 million, indicating high expenditure against low revenue.
• The company completed a public offering resulting in gross proceeds of approximately $5 million, which may enhance its liquidity position.

Future Outlook:

• Nexalin is focusing on gaining FDA approvals for its new Generation 2 and Generation 3 devices, expected to bring new revenue opportunities.
• Plans for decentralized clinical trials in the U.S., Brazil, and China for the new devices are on the agenda for 2025.
• The potential launch of a virtual clinic to cater to mental health needs is under development, indicating an innovative approach to market entry.

Nexalin Technology aims to stabilize and grow its business through strategic advancements in product offerings and operational adjustments. However, rising losses and ongoing regulatory hurdles present significant challenges ahead.